EliseAI builds AI agents that handle routine conversations and administrative work for housing operators and medical practices, connecting customer requests to business workflows. Its EliseCRM platform brings property teams' prospect and resident conversations into shared profiles, calendars, and task queues. The assistants answer calls and messages, schedule apartment tours or patient appointments, and keep staff informed when an interaction needs human attention. Customers buy access to its software and connect it to property management systems, medical records, and scheduling tools used by their teams. EliseAI was founded in 2017 and is headquartered in New York City.
Work here?Claim your company
Industries
Company Size
501-1,000
Company Stage
Series F
Total Funding
$741.9M
Headquarters
New York, NY
Founded
2017
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$741.9M
Above
Industry Average
Funded Over
7 Rounds
Follow the AI money to tomorrow's job description. This analysis synthesizes 8 sources published the week ending Oct 20, 2026. Editorial analysis by the PhysEmp Editorial Team. On Oct. 13, Suki announced a $90 million Series E and said where the money goes: AI agents that handle the work after the visit ends, such as referrals, prior authorizations for new medications, order entry and follow-up scheduling. The same day, Northwestern Medicine put OpenEvidence inside its Epic record and Johns Hopkins Medicine signed on with the same company to rethink how physicians are trained. Read together, the week says less about which vendor is winning than about which parts of a physician's day investors expect software to absorb next. That is the employment question inside PhysEmp's AI in Physician Employment & Clinical Practice coverage. Funding rounds are forecasts. They tell you which tasks companies believe health systems will pay to automate, and by extension which tasks will be left on the physician's plate and which new ones will be added to it. The money has moved past the note. Ambient scribing was the first wave. Healthcare Dive notes that Ambience Healthcare raised $243 million and Abridge $300 million last year. The rounds of the past month are aimed somewhere else. Heidi, which raised $340 million at a $900 million valuation on Sept. 22, began as a scribe and now says it is moving from documentation into "supervised action": administrative automation plus support for clinical decisions and reasoning. Its CEO, Thomas Kelly, described the shift as going "from documenting care to helping clinicians act on it." Heidi's annual recurring revenue went from $1 million to $50 million in two years, and Beth Israel Lahey Health has extended its scribe to all of its physicians. Suki's pitch follows the same arc. According to MarketScale's breakdown of the round, the company works with more than 250 healthcare organizations, saw patient encounters on its tools grow more than 190% year over year in 2026, and says its AI should extend into clinical reasoning, operational tasks and revenue-cycle work. The same report puts EliseAI's September round at $350 million and a $4 billion valuation, for a product that automates patient calls, referrals, scheduling, insurance verification, chart prep and follow-up for specialty physician groups. Add OpenEvidence's $250 million round, and four rounds reported between Sept. 22 and Oct. 13 total more than $1 billion. Nearly all of it is aimed at the hours between visits: the inbox, the referral, the prior auth, the chart prep. None of those tasks is a billable visit, which is why the question of who absorbs them, or who keeps the time once software does, matters so much to employed physicians. When a vendor automates a referral, the time saved does not automatically return to the physician. Unless a contract or compensation plan says otherwise, the employer decides whether those hours become shorter days, more visit slots, or a larger panel. Evidence lookup is becoming plumbing. The second pattern is quieter. OpenEvidence, now valued at $15 billion after a round led by Andreessen Horowitz and Byers Capital, says more than half of U.S. physicians use it regularly. It is already embedded in Epic at Mount Sinai and Sutter Health. At Northwestern Medicine, nurses, pharmacists and other clinical team members have signed in through their existing EHR credentials since Oct. 8, using it to check dosing, screen drug interactions and review guidelines. In September, the company made three of its production models free for verified clinicians. Suki is moving the same way from the other direction. Its Ask feature, launched Oct. 8, lets clinicians pull a patient's latest A1C, medications and allergies alongside UpToDate answers without leaving the documentation app. In an evaluation reported by MarketScale, clinician reviewers preferred answers that included patient context 83% of the time, though that figure measures preference, not outcomes or error rates. When reference lookup is free, embedded and open to the whole care team, knowing the answer stops being what distinguishes the physician. Judgment about whether the answer fits this patient, and the authority to act on it, becomes the scarce part. Employers will price that differently, and the first place it shows up is likely to be in how team-based models divide work between physicians and everyone else with the same login. Who answers for the agent's referral. Every one of these companies describes its product as supervised. That word carries the employment consequence. In a KevinMD essay published Oct. 16, gastroenterologist Brian Hudes, who discloses a commercial interest in AI governance, argues that responsibility should follow control: clinicians answer for clinical decisions, institutions for deployment and oversight, developers for what they build and change. He asks hospitals to trace every AI-assisted action to a named human who has a real path to override it. He also notes that the Joint Commission's voluntary AI certification, introduced in June, certifies an organization's governance rather than any individual product. Apply that to a referral drafted by an agent and filed under a physician's name. If the physician has no practical way to see why the agent chose a specialist, or no time allotted to check, the accountability is nominal while the liability is real. This is where the funding wave meets the job description: more tasks completed in the physician's name, fewer of them performed by the physician. A useful question for candidates in an interview: which AI tools act under my signature here, who chose them, and how much time does the schedule assume I spend reviewing what they produce? Training for the half of the job that stays. The academic side is already redrawing the profession around this split. Johns Hopkins and OpenEvidence plan a training model built on pathophysiology, first-principles reasoning, diagnostic skill and interpersonal skill, on the premise that the clinician's role shifts toward what cannot be automated. They disclosed no timeline or financial terms. A day later, a JAMA Viewpoint by Jesse Burk-Rafel and Robert Wachter warned of "never-skilling," where learners who start with AI skip the struggle that builds judgment, and called for an organizing principle for revising training. We have written less about the companies building these tools than about the liability and governance questions around them, and the size of this month's rounds suggests the products themselves deserve more attention. For recruiters, the practical point is already visible: the AI stack a system has chosen, and how it splits the saved time, is becoming part of the offer whether or not anyone puts it in the job posting. The number to watch is Suki's 190% encounter growth set against physician headcount at the systems deploying these agents. If encounters keep climbing while staffing plans stay flat, the productivity gain is being booked as volume. If systems start citing agent adoption to justify smaller recruiting targets or larger panels in 2027 budgets, the funding rounds of this fall will have been the first draft of next year's job descriptions.
EliseAI has been named a co-development partner with Nextech to expand AI voice agent capabilities for specialty medical practices. The partnership will integrate EliseAI's voice technology more deeply into Nextech's EHR and practice management software, which serves ophthalmology, dermatology, and orthopaedics practices. EliseAI's voice agents handle patient calls in over 30 languages, managing scheduling, rescheduling, and appointment cancellations whilst reading and writing directly into Nextech systems. The company's platform currently supports thousands of providers and processes more than 20 million conversations monthly. Practices using EliseAI have seen a 12% increase in patients booked, 8% fewer no-shows, and over 40% of lapsed patients booking appointments through recall outreach. EliseAI crossed $200 million in annual recurring revenue in 2026, marking five consecutive years of 100% year-over-year growth.
EliseAI named as co-development partner with Nextech to bring agentic voiceai to specialty practices. Already live with Nextech practices, EliseAI's voice agent will expand through co-developed integrations, deeper APIs, and joint support. October 09, 2026 10:00 ET | Source: EliseAI NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) - EliseAI, which builds AI automation for patient engagement, has been named a co-development partner for patient access by Nextech, a provider of EHR and practice management software for ophthalmology, dermatology, orthopedics, and other specialties. EliseAI's voice agents already fully handle patient calls for practices on Nextech, and EliseAI was selected for the strength of that technology in specialty care. The partnership takes the work further. The companies are co-developing deeper API integrations and aligning implementation, customer success, and support, so practices can cut no-shows and abandoned calls and give staff more time for patient care. EliseAI has built an agentic platform that follows each patient through their entire care journey, rather than a set of disconnected tools that each handle a single task. The platform supports every step, from the first referral through scheduling, intake forms, benefits verification, and payment to the follow-up that keeps care on track. EliseAI's voice agents answer every call, at any hour, in the patient's preferred language across 30+ languages. Reading and writing directly into the practice's Nextech system, they schedule, reschedule, and cancel appointments, answer common questions, and escalate to staff when needed. The same agent calls and texts patients for recall, reminders, and follow-up. It carries the history of every prior conversation, so patients never repeat themselves, and it follows each provider's scheduling protocols. "Patients judge a practice by whether someone picks up the phone. They also notice when a practice reaches out at the right moment," said Minna Song, co-founder and CEO of EliseAI. "Our agents hold more than 20 million conversations every month and currently support thousands of providers. That volume is why we handle the complexity of healthcare calls better than anyone, whether it's a glaucoma patient on a multi-visit monitoring schedule or a post-op cataract patient with urgent symptoms. Partnering with Nextech brings that to the specialty practices that already trust Nextech to run their business." Nextech practices will access EliseAI through their existing Nextech relationship, with streamlined onboarding and a single point of contact. The companies are co-developing a joint integration built on enhanced APIs and have aligned implementation, customer success, and support. "Our customers want to grow access and reduce front-desk burden without adding complexity," said John Beck, SVP of Strategy at Nextech. "By partnering with leading voice AI innovators like EliseAI and building the integration and support model together, we're giving practices a seamless experience within the Nextech platform they already know and trust. It's another step toward our vision of a connected ecosystem that brings the best capabilities to specialty practices." Specialty practices using EliseAI have seen 12% more patients booked on average, 8% fewer no-shows, and more than 40% of lapsed reached through recall outreach booking an appointment. With EliseAI's newest Referrals Automation product, incoming faxes are processed and converted into a scheduled appointment within minutes. "Before Elise, we were fielding around 11,000 calls with the volume climbing quickly after our merger," said Amanda Moorefield, Vice President of Operations at TriaVision. "Elise has eased that workload and supports our patients, so our team spends less time addressing missed calls and catching up on voicemails." EliseAI and Nextech will be at the American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans this weekend. About Nextech Nextech provides intelligent, connected technology that helps specialty practices operate more easily and create meaningful patient experiences. With more than 25 years of expertise in ophthalmology, dermatology, orthopedics, plastic surgery, and med spas, Nextech blends specialty insight with thoughtful innovation to simplify workflows, reduce friction, and support practice growth. To learn more aboutNextechand its intelligent, connected solutions, visit www.nextech.com. About EliseAI EliseAI is an AI company transforming housing and healthcare - the two largest household expenses in America - through deep workflow automation. It serves specialty care groups, automating the end-to-end patient journey from the first inbound call through referrals, scheduling, insurance verification, chart prep, and follow-up. The company has handled over 100 million patient conversations to date, while delivering a better patient experience, freeing clinical staff to focus on care, and ensuring that no patient falls through the cracks. EliseAI crossed $200 million in ARR in 2026, marking five consecutive years of 100% year-over-year growth. The company is headquartered in New York with teams in San Francisco, Boston, Chicago, Austin, and Toronto. To learn more, visit https://eliseai.com/careers. Recommended reading.
EliseAI named as co-development partner with Nextech to bring agentic voiceai to specialty practices. * Oct 9, 2026 Updated Oct 9, 2026 NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) - EliseAI, which builds AI automation for patient engagement, has been named a co-development partner for patient access by Nextech, a provider of EHR and practice management software for ophthalmology, dermatology, orthopedics, and other specialties. EliseAI's voice agents already fully handle patient calls for practices on Nextech, and EliseAI was selected for the strength of that technology in specialty care. The partnership takes the work further. The companies are co-developing deeper API integrations and aligning implementation, customer success, and support, so practices can cut no-shows and abandoned calls and give staff more time for patient care. EliseAI has built an agentic platform that follows each patient through their entire care journey, rather than a set of disconnected tools that each handle a single task. The platform supports every step, from the first referral through scheduling, intake forms, benefits verification, and payment to the follow-up that keeps care on track. EliseAI's voice agents answer every call, at any hour, in the patient's preferred language across 30+ languages. Reading and writing directly into the practice's Nextech system, they schedule, reschedule, and cancel appointments, answer common questions, and escalate to staff when needed. The same agent calls and texts patients for recall, reminders, and follow-up. It carries the history of every prior conversation, so patients never repeat themselves, and it follows each provider's scheduling protocols. "Patients judge a practice by whether someone picks up the phone. They also notice when a practice reaches out at the right moment," said Minna Song, co-founder and CEO of EliseAI. "Our agents hold more than 20 million conversations every month and currently support thousands of providers. That volume is why we handle the complexity of healthcare calls better than anyone, whether it's a glaucoma patient on a multi-visit monitoring schedule or a post-op cataract patient with urgent symptoms. Partnering with Nextech brings that to the specialty practices that already trust Nextech to run their business." Nextech practices will access EliseAI through their existing Nextech relationship, with streamlined onboarding and a single point of contact. The companies are co-developing a joint integration built on enhanced APIs and have aligned implementation, customer success, and support. "Our customers want to grow access and reduce front-desk burden without adding complexity," said John Beck, SVP of Strategy at Nextech. "By partnering with leading voice AI innovators like EliseAI and building the integration and support model together, we're giving practices a seamless experience within the Nextech platform they already know and trust. It's another step toward our vision of a connected ecosystem that brings the best capabilities to specialty practices." Specialty practices using EliseAI have seen 12% more patients booked on average, 8% fewer no-shows, and more than 40% of lapsed reached through recall outreach booking an appointment. With EliseAI's newest Referrals Automation product, incoming faxes are processed and converted into a scheduled appointment within minutes. "Before Elise, we were fielding around 11,000 calls with the volume climbing quickly after our merger," said Amanda Moorefield, Vice President of Operations at TriaVision. "Elise has eased that workload and supports our patients, so our team spends less time addressing missed calls and catching up on voicemails." EliseAI and Nextech will be at the American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans this weekend. About Nextech Nextech provides intelligent, connected technology that helps specialty practices operate more easily and create meaningful patient experiences. With more than 25 years of expertise in ophthalmology, dermatology, orthopedics, plastic surgery, and med spas, Nextech blends specialty insight with thoughtful innovation to simplify workflows, reduce friction, and support practice growth. To learn more aboutNextechand its intelligent, connected solutions, visit www.nextech.com. About EliseAI EliseAI is an AI company transforming housing and healthcare - the two largest household expenses in America - through deep workflow automation. It serves specialty care groups, automating the end-to-end patient journey from the first inbound call through referrals, scheduling, insurance verification, chart prep, and follow-up. The company has handled over 100 million patient conversations to date, while delivering a better patient experience, freeing clinical staff to focus on care, and ensuring that no patient falls through the cracks. EliseAI crossed $200 million in ARR in 2026, marking five consecutive years of 100% year-over-year growth. The company is headquartered in New York with teams in San Francisco, Boston, Chicago, Austin, and Toronto. To learn more, visit https://eliseai.com/careers. Media gallery Sections. Newsletters. News update. Would you like to receive our daily news? Signup today!
EliseAI's $350 million raise at a $4 billion valuation puts vertical AI for housing and healthcare to the test. EliseAI has raised $350 million at a $4 billion valuation, a big private-market bet that AI will create durable value not by answering open-ended prompts but by taking over repetitive, regulated work inside apartment operations and healthcare administration. The round, announced Sept. 29, matters because it suggests investors are rewarding distribution, workflow coverage and revenue in essential services over the more familiar story of model demos and chatbot novelty. The question behind the headline is simpler than the financing mechanics: is EliseAI showing that vertical AI can genuinely improve the economics of housing and healthcare, or are investors paying ahead of proof that those gains reach renters, patients and workers rather than just owners, providers and the vendor itself? Why this round stands out. EliseAI said the financing was led by Andreessen Horowitz and Bessemer Venture Partners, with participation from Ontario Teachers' Pension Plan, Sapphire Ventures and Navitas Capital. According to Fortune, the round consisted entirely of primary capital and nearly doubled the company's valuation from the $2.2 billion attached to its $250 million Series E about 13 months earlier. That matters for two reasons. First, primary capital means the money is going into the company rather than mainly to existing shareholders cashing out. Second, the valuation implies that investors believe EliseAI has moved beyond experiment status. The company says it now generates more than $200 million in annual recurring revenue, a figure that has not been publicly audited, and reaches 6.5 million housing units. In its own Sept. 29 announcement, EliseAI described that footprint as one in five U.S. multifamily apartments; a syndicated company release described it as one in six. Either way, the claimed reach is large enough to make the company more than a niche tool. EliseAI says it will use the new money to expand product development and grow engineering, deployment and sales across North America, including a second engineering hub in San Francisco alongside its New York headquarters. That hiring plan fits the business it has built. EliseAI was founded around operational workflows in property management and healthcare administration, not as a general-purpose assistant. Its products handle leasing, resident communications, scheduling and other repetitive service and back-office processes, and the company says it is pushing further into day-to-day operations. The case investors are buying. The strongest argument for EliseAI is not that it has a flashier model than everyone else. It is that narrow, industry-specific automation can be harder to replace once it is embedded in the messier parts of real work: routing inquiries, handling follow-ups, scheduling, intake, document collection and escalating exceptions to humans. That is the core vertical-AI pitch. In sectors like housing and healthcare, the value sits less in raw model performance than in integrations, workflow rules, operational data and the ability to expand inside an account after landing an initial use case. A landlord or healthcare operator is not buying a chatbot for entertainment. They are buying fewer missed calls, faster responses, better coverage after hours, more consistent follow-up and, ideally, a measurable lift in revenue or operating efficiency. EliseAI is presenting exactly that story. In its Sept. 29 announcement, the company said that across the units it serves, occupancy is two percentage points higher, residents are seven percentage points more likely to renew and net operating income rises by as much as 20%. If those gains hold up, they would help explain the valuation. A vendor that can reliably improve occupancy and renewals at scale becomes part of the economic engine of a property, not just another software line item. The same logic applies in healthcare administration, where missed messages, scheduling bottlenecks and intake delays can be expensive and frustrating. Here too, the attraction is not novelty. It is throughput. What the valuation does not settle. The problem is that the most important operating claims are still claims. The public record does not spell out the methodology behind EliseAI's occupancy, renewal or NOI figures, and it does not show the sample size, time period, comparison group or statistical controls. A stronger property cohort, local market conditions, pricing changes or broader service improvements could help produce the same results. That does not make EliseAI wrong. It does mean the round should be read as a market signal, not as independent proof. The same caution applies to reach and revenue. More than $200 million in ARR and millions of covered units indicate real distribution, but they do not answer the questions enterprise buyers should care about next: retention, gross margin, customer concentration, implementation cost, contract length, churn and how much of the business comes from housing versus healthcare. None of that was disclosed in the announcement. There is also the human side of automation. Property management and healthcare administration are full of repetitive tasks, but they also involve fair-housing obligations, personal and medical information, and situations where a scripted response is not enough. A system that handles high volumes of messages can improve speed while still creating new risks if its classifications, routing or communications are wrong. At scale, a small error can propagate across many properties or care sites before anyone catches it. That is why the real diligence questions are operational, not theatrical. How much of the workflow is automated? How often are exceptions kicked to a human? How fast can staff audit or reverse a bad routing decision? What controls govern data access? In housing, how are automated communications tested for fair-housing compliance, and what is the appeal path for a resident who believes the system got something wrong? In healthcare, where the public materials are thinner on compliance details, what is reviewed by people, what is logged, and who is accountable for high-impact administrative decisions? Who is likely to benefit. Investors clearly see a company with traction in hard-to-serve industries. Fortune reported this was the fourth financing involving a16z and Bessemer since 2023, a sign that existing backers believe the company's distribution advantage is strengthening. EliseAI also says its revenue has doubled year over year for five consecutive years, which, if sustained, would help explain why fresh capital arrived at a sharply higher price. But the next phase of the story is less about whether AI can answer leasing or scheduling inquiries and more about who captures the productivity it creates. Owners and providers may gain higher occupancy or lower administrative cost. The vendor may gain pricing power if it becomes deeply embedded. Frontline staff may be pushed into higher-value exception handling, or see hours reduced. Renters and patients may get faster responses, or they may find it harder to reach a person when the automated path fails. That is the lasting significance of EliseAI's raise. It shows that private capital is ready to treat vertical AI in essential services as infrastructure. What it does not yet show, at least in the public record, is how consistently the gains are measured, how widely they are shared, or how safely the system behaves when the workflow stops being routine. For landlords, healthcare operators and enterprise buyers, the useful scorecard now is not just ARR and valuation, but retention, workflow coverage, escalation rates, implementation time, compliance controls and independently measured outcomes. Emily Johnson, a seasoned journalist with a penchant for tech innovations and digital culture, has been enlightening BizTech Weekly's readers since its inception. With a background in computer science and a master's in journalism, Emily bridges the gap between complex tech concepts and everyday usability, making her columns a must-read for tech enthusiasts and novices alike.
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
501-1,000
Company Stage
Series F
Total Funding
$741.9M
Headquarters
New York, NY
Founded
2017
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs